Janux Therapeutics Ownership | Who Owns Janux Therapeutics?


OverviewForecastRevenueFinancialsChart

Janux Therapeutics Ownership Summary


Janux Therapeutics is owned by 97.49% institutional investors, 1.49% insiders, and 1.01% retail investors. Ra capital management is the largest institutional shareholder, holding 17.86% of JANX shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 3.67% of its assets in Janux Therapeutics shares.

JANX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockJanux Therapeutics97.49%1.49%1.01%
SectorHealthcare Stocks 50.51%12.37%37.12%
IndustryBiotech Stocks 48.95%12.07%38.98%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ra capital management11.19M17.86%$171.87M
Blackrock funding, inc. /de6.13M9.79%$94.23M
Janus henderson group4.20M6.77%$58.28M
Prosight management, lp3.80M6.07%$58.44M
State street3.00M4.80%$46.16M
Blackrock2.34M4.78%$98.19M
Paradigm biocapital advisors lp2.92M4.72%$71.37M
Vanguard group2.91M4.69%$40.11M
Fmr2.41M3.85%$37.06M
Federated hermes2.35M3.75%$36.14M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Prosight management, lp3.80M10.07%$58.44M
Avalon ventures management53.30K9.17%$1.30M
Bioimpact capital614.28K2.46%$15.01M
Paradigm biocapital advisors lp2.92M2.03%$71.37M
Ra capital management11.19M1.49%$171.87M
Lion point capital, lp19.00K1.40%$291.84K
Rangeley capital97.98K1.37%$1.50M
Bml capital management154.96K1.35%$2.38M
Nano cap new millennium growth fund l p56.00K0.66%$860.16K
Tcg crossover management1.79M0.66%$27.49M

Top Buyers

HolderShares% AssetsChange
Federated hermes2.35M0.05%2.30M
Two sigma investments, lp1.21M0.01%1.09M
Holocene advisors, lp1.02M0.17%1.02M
D. e. shaw1.10M0.01%998.11K
Citadel advisors1.20M0.00%848.56K

Top Sellers

HolderShares% AssetsChange
Ecor1 capital---1.47M
Deep track capital, lp---1.19M
Janus henderson group4.20M0.03%-1.15M
Logos global management lp---1.00M
Rtw investments, lp---1.00M

New Positions

HolderShares% AssetsChangeValue
Holocene advisors, lp1.02M0.17%1.02M$54.35M
Sixth street partners management company369.19K0.00%369.19K$5.67M
Panagora asset management269.11K0.01%269.11K$4.13M
Thrivent financial for lutherans115.03K0.00%115.03K$1.77M
Aqr capital management108.08K0.00%108.08K$1.66M

Sold Out

HolderChange
Bayforest capital-3.00
Massmutual trust co fsb/adv-6.00
Corecap advisors-9.00
Stephens consulting-15.00
Capital performance advisors llp-17.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20262021.00%61,095,0922.53%971.08%1184.42%47-9.62%
Mar 31, 2026117-37.77%14,603,619-76.52%230.23%73-35.96%23-43.90%
Dec 31, 2025139-23.20%36,407,138-44.13%580.53%832.47%29-53.23%
Sep 30, 2025172-1.71%64,553,5911.68%1040.99%79-14.13%5915.69%
Jun 30, 2025180-6.25%65,438,049-1.58%1050.91%93-21.19%5323.26%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Fidelity Growth Compy Commingled Pl S2.20M3.67%2.89K
Fidelity Growth Compy Commingled Pl O1.65M3.16%20.65K
State Street® SPDR® S&P® Biotech ETF1.90M3.11%4.36K
Fidelity Growth Company Fund1.56M2.60%-9.34K
Federated Hermes MDT Small Cap Core IS1.28M2.11%1.28M
Federated Hermes MDT SCC Institutional1.28M2.10%1.28M
Vanguard Morn Total Stk Mkt Idx Investor1.26M2.07%38.00K
Vanguard Total Stock Mkt Idx Inv1.26M2.07%38.00K
Vanguard MStar Total Stk Mkt Idx Invest1.26M2.07%-
iShares Russell 2000 ETF1.10M1.81%-19.58K

Recent Insider Transactions


DateNameRoleActivityValue
Jun 02, 2026Doyle Janeen Noel Chief Corp. & Bus. Dev. OfcrSell$56.94K
May 11, 2026Dobek Maria Vice President, AccountingSell$28.88K
Jan 02, 2026Meyer Andrew Hollman Chief Business OfficerSell$25.80K
Jan 02, 2026DiRaimondo Thomas Chief Scientific OfficerSell$34.39K
Jan 02, 2026Campbell David Alan President and CEOSell$110.83K

Insider Transactions Trends


DateBuySell
2026 Q3--
2026 Q2-2
2026 Q1-6
2025 Q4-4
2025 Q2-3

JANX Ownership FAQ


Who Owns Janux Therapeutics?

Janux Therapeutics shareholders are primarily institutional investors at 97.49%, followed by 1.49% insiders and 1.02% retail investors. The average institutional ownership in Janux Therapeutics's industry, Biotech Stocks , is 48.95%, which Janux Therapeutics exceeds.

Who owns the most shares of Janux Therapeutics?

Janux Therapeutics’s largest shareholders are Ra capital management (11.19M shares, 17.86%), Blackrock funding, inc. /de (6.13M shares, 9.79%), and Janus henderson group (4.2M shares, 6.77%). Together, they hold 34.42% of Janux Therapeutics’s total shares outstanding.

Does Blackrock own Janux Therapeutics?

Yes, BlackRock owns 4.78% of Janux Therapeutics, totaling 2.34M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 98.19M$. In the last quarter, BlackRock increased its holdings by 650.02K shares, a 38.37% change.

Who is Janux Therapeutics’s biggest shareholder by percentage of total assets invested?

Prosight management, lp is Janux Therapeutics’s biggest shareholder by percentage of total assets invested, with 10.07% of its assets in 3.8M Janux Therapeutics shares, valued at 58.44M$.

Who is the top mutual fund holder of Janux Therapeutics shares?

Fidelity Growth Compy Commingled Pl S is the top mutual fund holder of Janux Therapeutics shares, with 3.67% of its total shares outstanding invested in 2.2M Janux Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools